A detailed history of Perceptive Advisors LLC transactions in Arcellx, Inc. stock. As of the latest transaction made, Perceptive Advisors LLC holds 3,888,669 shares of ACLX stock, worth $344 Million. This represents 8.48% of its overall portfolio holdings.

Number of Shares
3,888,669
Previous 3,889,739 0.03%
Holding current value
$344 Million
Previous $215 Million 51.27%
% of portfolio
8.48%
Previous 6.21%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$50.91 - $86.61 $54,473 - $92,672
-1,070 Reduced 0.03%
3,888,669 $325 Million
Q2 2024

Aug 14, 2024

SELL
$49.74 - $66.98 $2.18 Million - $2.93 Million
-43,817 Reduced 1.11%
3,889,739 $215 Million
Q1 2024

May 15, 2024

SELL
$51.85 - $73.49 $31.7 Million - $44.9 Million
-611,253 Reduced 13.45%
3,933,556 $274 Million
Q4 2023

Feb 14, 2024

BUY
$31.75 - $57.99 $18.4 Million - $33.6 Million
578,831 Added 14.59%
4,544,809 $252 Million
Q3 2023

Nov 14, 2023

SELL
$31.51 - $37.4 $1.59 Million - $1.89 Million
-50,419 Reduced 1.26%
3,965,978 $142 Million
Q2 2023

Aug 14, 2023

BUY
$27.49 - $46.9 $4.8 Million - $8.19 Million
174,658 Added 4.55%
4,016,397 $127 Million
Q1 2023

May 15, 2023

BUY
$26.92 - $33.94 $33.5 Million - $42.2 Million
1,243,434 Added 47.86%
3,841,739 $118 Million
Q4 2022

Feb 14, 2023

BUY
$17.18 - $33.0 $2.28 Million - $4.39 Million
132,900 Added 5.39%
2,598,305 $80.5 Million
Q3 2022

Nov 14, 2022

BUY
$16.67 - $22.04 $22.1 Million - $29.2 Million
1,323,415 Added 115.89%
2,465,405 $46.3 Million
Q2 2022

Aug 15, 2022

BUY
$7.21 - $24.43 $8.23 Million - $27.9 Million
1,141,990 New
1,141,990 $20.6 Million

Others Institutions Holding ACLX

About Arcellx, Inc.


  • Ticker ACLX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,819,200
  • Market Cap $3.88B
  • Description
  • Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It...
More about ACLX
Track This Portfolio

Track Perceptive Advisors LLC Portfolio

Follow Perceptive Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Perceptive Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Perceptive Advisors LLC with notifications on news.